ESG

With new CEO Antonio Martinez Descalzo, Novella is scaling its cell-cultured ingredients to disrupt the fragile botanical supply chain.

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.

After selling assets and raising cash, Q32 Bio focuses all its resources on bempikibart, a novel drug for hair loss, with pivotal data due in 2026.

Eve Air Mobility, Alt Air, and Skyports team up to launch eVTOL services in NSW and Queensland, with an eye on the Brisbane 2032 Olympic Games.

A new industry report claims mining for green minerals is low-emission, but reveals the real climate fight is decarbonizing steel and aluminum production.

A new partnership aims to deploy over a billion dollars into restoring global ecosystems, betting on high-integrity carbon credits to fund the fight for nature.

The tech giant's high placement on TIME's 2026 list is driven by a unique blend of sustainable practices, AI innovation, and employee satisfaction.

ViruSure's new GMP-validated test using Oxford Nanopore sequencing promises to slash drug safety testing times, boosting supply chain resilience.

CCM Hockey and Mattel's Barbie team up for a vibrant new gear collection, aiming to boost inclusion and tap into the booming women's hockey market.

K-pop sensation Kim Sejeong is the new face of REJURAN, a move merging celebrity appeal with advanced skin science to expand K-beauty's global reach.

A new chip promises to slash IoT device power use by up to 90%, paving the way for 'install-and-forget' sensors and a more sustainable connected world.

A new line of ultra-pure proteins with endotoxin levels 10x below the standard could revolutionize advanced therapies and fix a key source of error in science.

With $11.8M in fresh capital, Axiom Trust is emerging from stealth to modernize the archaic trust administration industry ahead of a massive wealth shift.

Telehealth firm Direct Meds offers cheap GLP-1 drugs, but an FDA warning for "false claims" and the end of drug shortages cast a long shadow on its model.

Biosolutions leader Novonesis ranks 6th on the prestigious list, a recognition driven by employee feedback and its deep roots in the state's biotech economy.

As private equity giant EIG sells its entire stake, Diversified Energy counters by repurchasing nearly half the shares in a bold vote of confidence.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

As Cal-Maine preps its Q3 report, investors watch if its pivot to prepared foods and specialty eggs can offset plunging prices and new avian flu threats.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.

BETA Technologies will launch electric air services across 10 states, deploying its ALIA aircraft for cargo, medical, and critical logistics missions.